Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atovaquone effects on hypoxia in non-small cell lung carcinoma
NCT02628080Phase 1Completed
- Sponsor
- University of Oxford
- Start
- May 2016
- Primary completion
- Oct 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of atovaquone in non-small cell lung carcinoma (NSCLC), sponsored by University of Oxford. Primary endpoint: Percentage change in reduction of hypoxia by atovaquone. Started May 2016; status: completed.
02
Drugs
atovaquone
03
Conditions
non-small cell lung carcinoma (NSCLC)
Beyond the preview
Go deeper on NCT02628080.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02628080.